Pre-treatment tumour perfusion parameters and initial RECIST response do not predict long-term survival outcomes for patients with head and neck squamous cell carcinoma treated with induction chemotherapyCitation formats

  • External authors:
  • Natalie Lowe
  • Lucy Kershaw
  • Jonathan M Bernstein
  • Stephanie B Withey
  • Kathleen Mais
  • Jarrod Homer
  • Nicholas Slevin
  • Suzanne C. Bonington
  • Bernadette M Carrington

Standard

Pre-treatment tumour perfusion parameters and initial RECIST response do not predict long-term survival outcomes for patients with head and neck squamous cell carcinoma treated with induction chemotherapy. / Lowe, Natalie; Kershaw, Lucy; Bernstein, Jonathan M; Withey, Stephanie B; Mais, Kathleen; Homer, Jarrod; Slevin, Nicholas; Bonington, Suzanne C.; Carrington, Bernadette M; West, Catharine.

In: P L o S One, 28.03.2018.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Lowe, Natalie ; Kershaw, Lucy ; Bernstein, Jonathan M ; Withey, Stephanie B ; Mais, Kathleen ; Homer, Jarrod ; Slevin, Nicholas ; Bonington, Suzanne C. ; Carrington, Bernadette M ; West, Catharine. / Pre-treatment tumour perfusion parameters and initial RECIST response do not predict long-term survival outcomes for patients with head and neck squamous cell carcinoma treated with induction chemotherapy. In: P L o S One. 2018.

Bibtex

@article{3e3f380bae8e4ed9b1f4761192a34e07,
title = "Pre-treatment tumour perfusion parameters and initial RECIST response do not predict long-term survival outcomes for patients with head and neck squamous cell carcinoma treated with induction chemotherapy",
abstract = "Objectives Previously, we showed that pre-treatment tumour plasma perfusion (Fp) predicts RECIST response to induction chemotherapy (ICT) in locoregionally advanced head and neck squamous cell carcinoma (HNSCC). The aim here was to determine whether the pre-treatment tumour Fp estimate, changes in tumour Fp or RECIST response post 2 cycles of ICT were prognostic for long-term survival outcomes. Methods A prospective study enrolled patients with high stage HNSCC treated with docetaxel (T), cisplatin (P) and 5-fluorouracil (F) (ICT) followed by synchronous cisplatin and intensity modulated radiotherapy. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) before and after two cycles of ICT was used to measure Fp and RECIST response. Results Forty-two patients were recruited and 37 underwent two scans. The median follow-up was 36 (range 23–49) months. Pre-treatment tumour Fp (stratified by median) was not prognostic for overall survival (p = 0.42), disease specific survival (p = 0.20) and locoregional control (p = 0.64). Neither change in tumour Fp nor RECIST response post two cycles of ICT was prognostic for any outcome (p>0.21). Conclusion DCE-MRI parameters do not predict long-term survival outcomes following ICT and RECIST response to ICT may not be an appropriate endpoint to determine early efficacy of a treatment in HNSCC patients",
author = "Natalie Lowe and Lucy Kershaw and Bernstein, {Jonathan M} and Withey, {Stephanie B} and Kathleen Mais and Jarrod Homer and Nicholas Slevin and Bonington, {Suzanne C.} and Carrington, {Bernadette M} and Catharine West",
year = "2018",
month = mar,
day = "28",
doi = "10.1371/journal.pone.0194841",
language = "English",
journal = "PL o S One",
issn = "1932-6203",
publisher = "Public Library of Science",

}

RIS

TY - JOUR

T1 - Pre-treatment tumour perfusion parameters and initial RECIST response do not predict long-term survival outcomes for patients with head and neck squamous cell carcinoma treated with induction chemotherapy

AU - Lowe, Natalie

AU - Kershaw, Lucy

AU - Bernstein, Jonathan M

AU - Withey, Stephanie B

AU - Mais, Kathleen

AU - Homer, Jarrod

AU - Slevin, Nicholas

AU - Bonington, Suzanne C.

AU - Carrington, Bernadette M

AU - West, Catharine

PY - 2018/3/28

Y1 - 2018/3/28

N2 - Objectives Previously, we showed that pre-treatment tumour plasma perfusion (Fp) predicts RECIST response to induction chemotherapy (ICT) in locoregionally advanced head and neck squamous cell carcinoma (HNSCC). The aim here was to determine whether the pre-treatment tumour Fp estimate, changes in tumour Fp or RECIST response post 2 cycles of ICT were prognostic for long-term survival outcomes. Methods A prospective study enrolled patients with high stage HNSCC treated with docetaxel (T), cisplatin (P) and 5-fluorouracil (F) (ICT) followed by synchronous cisplatin and intensity modulated radiotherapy. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) before and after two cycles of ICT was used to measure Fp and RECIST response. Results Forty-two patients were recruited and 37 underwent two scans. The median follow-up was 36 (range 23–49) months. Pre-treatment tumour Fp (stratified by median) was not prognostic for overall survival (p = 0.42), disease specific survival (p = 0.20) and locoregional control (p = 0.64). Neither change in tumour Fp nor RECIST response post two cycles of ICT was prognostic for any outcome (p>0.21). Conclusion DCE-MRI parameters do not predict long-term survival outcomes following ICT and RECIST response to ICT may not be an appropriate endpoint to determine early efficacy of a treatment in HNSCC patients

AB - Objectives Previously, we showed that pre-treatment tumour plasma perfusion (Fp) predicts RECIST response to induction chemotherapy (ICT) in locoregionally advanced head and neck squamous cell carcinoma (HNSCC). The aim here was to determine whether the pre-treatment tumour Fp estimate, changes in tumour Fp or RECIST response post 2 cycles of ICT were prognostic for long-term survival outcomes. Methods A prospective study enrolled patients with high stage HNSCC treated with docetaxel (T), cisplatin (P) and 5-fluorouracil (F) (ICT) followed by synchronous cisplatin and intensity modulated radiotherapy. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) before and after two cycles of ICT was used to measure Fp and RECIST response. Results Forty-two patients were recruited and 37 underwent two scans. The median follow-up was 36 (range 23–49) months. Pre-treatment tumour Fp (stratified by median) was not prognostic for overall survival (p = 0.42), disease specific survival (p = 0.20) and locoregional control (p = 0.64). Neither change in tumour Fp nor RECIST response post two cycles of ICT was prognostic for any outcome (p>0.21). Conclusion DCE-MRI parameters do not predict long-term survival outcomes following ICT and RECIST response to ICT may not be an appropriate endpoint to determine early efficacy of a treatment in HNSCC patients

U2 - 10.1371/journal.pone.0194841

DO - 10.1371/journal.pone.0194841

M3 - Article

JO - PL o S One

JF - PL o S One

SN - 1932-6203

ER -